Bioelectronic Medicine

Selected news for the healthcare topic - Bioelectronic Medicine, collected since 10/2017. Recent stories appear in Nasdaq and tmcnet.com. This healthcare topic shares news with Medical Research, Northwell Health, electroCore, Kevin J. Tracey and dozens of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
2/9/2021 electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery stockhouse.com ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study&CloseCurlyDoubleQuote: ; in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James&CloseCurlyQuote: ;s University Hospital in ...
2/9/2021 electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery gurufocus.com ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. ( ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James’s University Hospital in Leeds, England ...
2/4/2021 electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference | IT Business Net theusdaily.com News electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021. Event Details: Date: Wednesday, February 17Time ...
2/3/2021 electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference gurufocus.com ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. ( ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021.Event Details:Date: Wednesday, February 17Time: 12:30pm – 12:55pm ETA live webcast of the presentation will be available on the Investors section ...
2/2/2021 electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke tmcnet.com ... Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized ...
2/2/2021 Study Supports Bioelectronic Medicine to Treat Rheumatoid Arthritis neuro-central.com Study Supports Bioelectronic Medicine to Treat Rheumatoid Arthritis The Feinstein Institutes CEO Kevin J. Tracey, MD, comments in Lancet Rheumatology about study that electronically stimulated the vagus nerve to treat the diseaseMANHASSET, N.Y.–(BUSINESS WIRE)–The burgeoning scientific field of bioelectronic medicine , which features the use of electronic devices to stimulate nerves to treat disease, has shown great promise in alleviating serious health conditions. In a Lancet Rheumatology ...
2/2/2021 Study Supports Bioelectronic Medicine to Treat Rheumatoid Arthritis financialbuzz.com The burgeoning scientific field of bioelectronic medicine , which features the use of electronic devices to stimulate nerves to treat disease, has shown great promise in alleviating serious health conditions. In a Lancet Rheumatology editorial published , Feinstein Institutes for Medical Research president and CEO Kevin J. Tracey, MD , discussed a recent clinical study that used a hand-held battery-operated electronic device to treat patients suffering from moderate to severe rheumatoid ...
2/2/2021 electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke Business Insider ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society ...
2/1/2021 SetPoint Medical Announces First Patient Enrolled in the RESET-RA Study biomedreports.com Tweet VALENCIA, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) VALENCIA, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced the enrollment of the first patient in the company’s RESET-RA study. The study received an Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to evaluate SetPoint Medical’s proprietary bioelectronic platform in ...
1/29/2021 Machine learning tool predicts respiratory failure in COVID-19 patients financialbuzz.com ... the Journal of Medical Internet Research .This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005971/en/Dr. Theodoros Zanos, assistant professor at the Feinstein Institutes’ Institute of Bioelectronic Medicine (Credit: The Feinstein Institutes for Medical Research).Scientists collected and analyzed electronic health record (EHR) data from 11,525 patients who were admitted across 13 Northwell Health hospitals, New York’s largest health system, between ...
1/27/2021 electroCore, Inc. Announces Inclusion of gammaCore Sapphireâ„¢ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22 tmcnet.com ... electroCore, Inc. Announces Inclusion of gammaCore Sapphire™ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22 ROCKAWAY, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire (nVNS) has been included in a new long-term reimbursement policy launched by Matthew Whitty, Director of Innovation Research and Life Sciences and Chief Executive of the Accelerated ...
1/26/2021 electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada gurufocus.com ROCKAWAY, N.J., electroCore, Inc. ( ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada, supplying therapy to patients suffering with primary headache disorders.“We are delighted to partner with RSK Medical as we look to ...
1/26/2021 electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada tmcnet.com ... RSK Medical Inc. in Canada [January 26, 2021] electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus ...
1/24/2021 Schumer: Articles of impeachment to be read in the Senate at 7 p.m. Monday newsday.com ... inaugurationLive coverage: Joe Biden's Inauguration19:51 Farewell Address of President Donald J. Trump2:32 Possible changes to immigration policies under Biden2:56 LIers hopeful Biden's vaccine plan will work1:41 The future of bioelectronic medicine 25:06 President-elect Joe Biden speaks2:53 end 20:45 end4:46 Jim Jordan3:26 Lee Zeldin7:18 Nancy Pelosi7:21:57 House discussing filing articles of impeachment against Trump for second time1:48 LIers ...
1/21/2021 electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients gurufocus.com ROCKAWAY, N.J., electroCore, Inc. ( ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is based on guidance produced in 2019 by the U.K. National Institute for Health and Care Excellence (“NICE”), which states that gammaCore, when used alongside standard ...
1/21/2021 electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients forextv.com ... Use of gammaCore™ in NHS Scotland Cluster Headache Patients Posted by: GlobeNewswire in Top News 2 mins ago ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is ...
1/21/2021 electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCoreâ„¢ in NHS Scotland Cluster Headache Patients tmcnet.com ... 2021] electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache. The SHTG publication is ...
1/21/2021 ECOR Stock Price Increases Over 15% Pre-Market: Why It Happened pulse2.com ... Over 15% Pre-Market: Why It Happened The stock price of electroCore, Inc. (NASDAQ: ECOR) is trading at over 15% pre-market today. This is why it happened.The stock price of commercial-stage bioelectronic medicine company electroCore, Inc. (NASDAQ: ECOR) is trading at over 15% pre-market today. Investors appear to be responding to the company publishing a Scottish Health Technology Group (SHTG) adaptation for NHS Scotland on the ...
1/19/2021 electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for "Non-Invasive Vagus Nerve Stimulator" tmcnet.com ... 19, 2021] electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for "Non-Invasive Vagus Nerve Stimulator" ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services (“CMS”) published its most recent Level II Healthcare Common Procedure Coding System (“HCPCS”) decisions on January 15, 2021, establishing a unique code ...
1/11/2021 electroCore Provides Business Update and Select Financial Guidance tmcnet.com ... 3.7 million, compares favorably to previously announced guidance of $4M December 31, 2020 cash and cash equivalents of $22.6M BASKING RIDGE, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the fourth quarter. “Notwithstanding the resurgence of COVID-19 case counts which began midway through the fourth quarter ...